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reatment of Heart Failure*
umudha Ramasubbu, MD,
ouglas L. Mann, MD, FACC
ouston, Texas
everal retrospective studies have suggested that the
-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) re-
uctase inhibitors (statins) may benefit patients with isch-
mic and nonischemic cardiomyopathy (1–5). However,
here are limited prospective data to suggest that statins are
eneficial once heart failure (HF) is established (6,7).
oreover, there are theoretic concerns that the routine use
f statins may be harmful in patients with HF. That is, one
xplanation for the observation that low circulating levels of
holesterol are associated with worse outcomes in patients
ith HF (8–10) is that circulating lipoproteins bind bacte-
See pages 332 and 338
ial endotoxins that have been absorbed from the edematous
ut of HF patients (the endotoxin-lipoprotein hypothesis)
11), thereby preventing endotoxin-induced inflammation
rom occurring. Theoretically, the lipid-lowering effect of
tatins might be deleterious by allowing unbound endotoxin
o activate immune cells to produce proinflammatory cyto-
ines (tumor necrosis factor [TNF], interleukin [IL]-1, and
L-6), which in turn might contribute to HF progression.
nother theoretic problem with the use of statins in HF is
elated to statins’ inhibitory effects on ubiquinone (CoQ10)
ynthesis, which might precipitate or aggravate HF by
reating problems with mitochondrial respiration (12).
hus, the safety and efficacy of statin use in HF is not clearly
nown.
In this issue of the Journal, Sola et al. (13) report on the
esults of a prospective double-blind placebo-controlled
tudy in which they randomized 108 patients (New York
eart Association [NYHA] functional class II to IV) with
on-ischemic HF and a left ventricular (LV) ejection
raction (EF) of 35% to atorvastatin (20 mg/day) or
lacebo for 12 months. These authors observed that LV EF
ncreased significantly in the atorvastatin group over the
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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y funds from the Cain scholarship.2-month follow-up period (0.33  0.05 to 0.37  0.04),
hereas patients in the placebo group experienced a decline
n EF during the same period (0.33 0.04 to 0.31 0.03).
n addition, the LV end-diastolic dimensions decreased
ignificantly in the cohort of patients treated with atorva-
tatin (57.1  5.9 mm to 53.4  5.1 mm), whereas LV
nd-diastolic dimension increased in the placebo group
56.1  5.9 to 60.3  5.1). The authors further noted that
here was an increase in erythrocyte superoxide dismutase
ctivity and significant reductions in serum levels of high
ensitivity C-reactive protein (hsCRP), IL-6, and the type 2
umor necrosis factor receptor in the atorvastatin group,
onsistent with a decrease in oxidative stress and inflamma-
ion. In a related paper also in this issue of the Journal,
leske et al. (14) report on a smaller study to determine the
ffect of aggressive statin therapy on patient safety and
urrogate biomarkers for HF. These authors randomized 15
atients (NYHA functional class I to III) with non-
schemic cardiomyopathy into a double-blinded, placebo-
ontrolled crossover trial. Patients already receiving maximal
edical therapy were treated with 80 mg of atorvastatin or
atching placebo for a 12-week period, with a minimum of
n 8-week washout period. Bleske et al. (14) evaluated
iomarkers that reflected cardiac remodeling (N-terminal-
ro brain natriuretic peptide), inflammation (hsCRP, the
ype 1 tumor necrosis factor [TNF] receptor), and endothe-
ial activation (vascular adhesion molecule-1, intercellular
dhesion molecule-1, soluble P-selectin). Although treat-
ent with high-dose atorvastatin was safe and resulted in a
ignificant decrease in low-density lipoprotein (LDL) con-
entrations (110  27 mg/dl to 55  18 mg/dl), there were
o significant differences between atorvastatin and placebo
ith respect to the surrogate biomarkers that were mea-
ured. Before addressing what these studies tell us about the
otential role of statins in the treatment of patients with
F, it is useful to digress for a moment in order to discuss
hat is know about the biologic properties of statins, as well
s the clinical effects of statins in HF that have been
bserved thus far.
vidence for the beneficial effects of HMG-CoA reduc-
ase inhibitors in experimental models and clinical trials
f HF. As shown in Figure 1, HMG-CoA reductase
nhibitors lower plasma cholesterol levels by inhibiting
MG-CoA reductase, the rate-limiting enzyme in the
evalonate pathway that is responsible for cholesterol
ynthesis. Importantly, intermediate products in the meva-
onate pathway include isoprenoids such as farnesylpyro-
hosphate (farnesyl-PP) and geranylgeranylpyrophosphate
geranylgeranyl-PP), which have been linked to activation
f downstream signaling pathways mediated by Ras and
ho, respectively. The Ras family of proteins is responsible
or cell proliferation and hypertrophy, whereas the Rho
amily of proteins is important for superoxide generation
nd cytoskeletal formation (15,16). Rho inhibition has also
een linked to increased expression of endothelial nitric
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January 17, 2006:342–4 Editorial Commentxide synthesis, which has a beneficial effect on endothelial
unction through increased nitric oxide production. Al-
hough the mechanism is less clear, statins also activate the
hosphatidylinositol 3=- kinase/Akt pathway, which is cou-
led to cytoprotective signaling pathways (17). On the basis
f the foregoing arguments, the lipid-independent effects of
tatins would be expected to be beneficial in HF patients.
xperimental models. Experimental infarct studies have
hown that treatment with statins leads to attenuation of
V remodeling and improved LV ejection performance
ithout directly affecting infarct size. The attenuation in
V remodeling was attributed to decreased cardiac myocyte
ypertrophy, decreased activation of matrix metalloprotein-
ses, and decreased fibrosis (18). Importantly, statins have
lso been shown to promote angiogenesis (19), mobilize
one marrow endothelial progenitor cells (20), result in
own-regulation of angiotensin type 1 receptors (21), and
ead to improved heart rate variability and baroreflex sensi-
ivity (22,23), any or all of which may have additional
eneficial effects on cardiac remodeling.
linical trials. Several retrospective analyses of clinical trial
atabases have suggested that, for patients with coronary
rtery disease, the use of statins has either reduced the
ncidence of HF (3) or reduced the mortality of patients
ith known HF (24,25). Given the known salutary effects of
tatins on outcomes in coronary artery disease, as well as the
igh prevalence of ischemic heart disease in HF trials, these
ndings are not surprising. More interesting, perhaps, is a
ecent study by Node et al. (7), which provides provisional
vidence for the beneficial lipid-independent effects of
tatins in HF patients. The authors showed that patients
n  51) with symptomatic nonischemic dilated cardiomy-
pathy (NYHA functional class II to III) who were ran-
omized to simvastatin for 14 weeks had an improvement in
YHA functional class; improved LV function; and signif-
cant decreases in circulating levels of plasma TNF, IL-6,
igure 1. The mevalonate pathway leads to the synthesis of cholesterol.
mportant intermediate products in the mevalonate pathway include
soprenoids such as farnesylpyrophosphate (farnesyl-PP) and geranylgera-
ylpyrophosphate (geranylgeranyl-PP), which have been linked to activa-
ion Ras- and Rho-mediated signaling. 3-hydroxy-3methylglutaryl coen-
yme A (HMG-CoA) reductase inhibitors decrease the synthesis of
soprenoids as well as cholesterol by blocking HMG-CoA reductase.nd brain natriuretic peptide. In a smaller study, Laufs et al. o6) randomized 15 patients with non-ischemic dilated
ardiomyopathy (NYHA functional class II to III) to
erivastatin (0.4 mg) or placebo for an average treatment
eriod of 20 weeks. They observed that statin treatment
esulted in an improvement in quality of life and exercise
apacity that was accompanied by decreased plasma concen-
rations of troponin T, hsCRP, plasminogen activator
nhibitor-1, and TNF. Finally, in a retrospective analysis of
heir cardiac transplant database (n  551 patients), Hor-
ich et al. (1) showed that statin use was associated with
mproved survival without the necessity for urgent heart
ransplantation in both ischemic and nonischemic HF
hazard ratio 0.41, 95% confidence interval 0.18 to 0.94).
hus, the results of the present study by Sola et al. (13) are
onsistent with previous observational and prospective stud-
es that have shown beneficial effects of statins in HF
atients. Moreover, this study extends prior observations by
emonstrating that treatment with statins leads to “reverse”
ardiac remodeling and suggests (but does not prove) that
he anti-inflammatory effects of statins may be through a
eduction in oxidative stress. In contrast, the study by Bleske
t al. (14) suggests that high-dose atorvastatin for a shorter
uration of time was safe but had no effect on HF
iomarkers. Although the reasons for these discrepant
ndings are not known, the most logical explanation (aside
rom the small numbers of patients) is that the patient
ohort studied by Bleske et al. had relatively mild HF and
hus had minimal activation of neurohormonal and inflam-
atory systems. Indeed, as noted by Bleske et al. (14), the
iomarkers chosen were “for the most part. . .in the range
hat. . .was considered normal” (14). Thus, on the basis of
he study design that was employed, one would not have
xpected to have observed striking changes in the panel of
iomarkers following statin treatment. Importantly, how-
ver, there were no obvious harmful effects of high-dose
tatins, despite the significant lipid lowering that was
bserved.
s there sufficient evidence to warrant the routine use of
tatins in patients with HF? There is substantial clinical
vidence that statins reduce the incidence of HF in patients
ith known coronary artery disease by reducing coronary
vents. Moreover, the increasing use of lipid-lowering
trategies in recent HF trials has not resulted in worsening
utcomes for the subsets of patients treated with statins.
ccordingly, the use of statins can be advocated in patients
ith HF with known coronary artery disease and elevated
evels of LDL, as recommended by current practice guide-
ines. However, the broader question of whether statins
hould be routinely used in all patients with HF, including
atients with ischemic HF with low or normal LDL levels
nd/or non-ischemic HF, remains unanswered. Given that
ur randomized clinical experience with statins in non-
schemic cardiomyopathy is limited to several small trials in
hich 100 patients have actually been treated, and given
hat we have no information with respect to the correct dose
f statins to use in these patients, it is premature to
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Editorial Comment January 17, 2006:342–4ecommend the routine use of statins for all HF patients.
ortunately, there are several ongoing large-scale clinical
utcome trials in HF patients (COntrolled Rosuvastatin
ultiNAtional trial in heart failure [CORONA], Gruppo
taliano per lo Studio della Sopravvivenza nell’Insufficienza
ardiaca [GISSI-HF] [Italian Group for the Study of the
urvival in Cardiac Insufficiency], and RosUvastatiN Im-
act on VEntricular Remodelling lipidS and cytokines
UNIVERSE]) that should provide a more definitive an-
wer to this important question. Although predicting out-
omes of ongoing clinical trials in HF is generally fraught
ith peril, the results of the study by Sola et al. (13) in the
urrent issue of the Journal, as well as the burgeoning
xperimental and clinical evidence supporting the safety and
tility of statins in patients with advanced HF, suggest that
tatin therapy will find much broader applicability in the
tandard treatment of HF patients in the foreseeable future.
eprint requests and correspondence: Dr. Douglas L. Mann,
aculty Center, 1709 Dryden Road, BCM620, Houston, Texas
7030. E-mail: dmann@bcm.tmc.edu.
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